Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

476.40 -6.02 (-1.25%)
Streaming Delayed Price Updated: 1:47 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
Decoding 7 Analyst Evaluations For United Therapeutics ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 7 Takes On United Therapeutics ↗
 
Via Benzinga
News headline image
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Peering Into United Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Look Into United Therapeutics Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Key Takeaways From United Therapeutics Analyst Ratings ↗
 
Via Benzinga
News headline image
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
News headline image
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
News headline image
U.S. Stock: United Therapeutics Corp ↗
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
News headline image
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today ↗
 
Via Benzinga
News headline image
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
From United Therapeutics Corporation
Via Business Wire
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
News headline image
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
Biohaven Stock Earns Relative Strength Rating Upgrade ↗
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings ↗
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
News headline image
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% ↗
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. 
Via Investor's Business Daily
News headline image
Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio? ↗
Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines. 
Via Benzinga
News headline image
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
News headline image
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.